Reviticell Kits: Unlocking the Potential of Regenerative Medicine

Share Article

Reviticell enters the next phase of commercializing single-use devices to bring standardization to an industry.

Reviticell has developed a medical device so that doctors can more safely and efficiently prepare regenerative medicine treatments. Reviticell Holdings Inc. (http://reviticell.com) is now entering the next phase of commercializing these single-use medical devices.

Reviticell has retained Kaleidoscope to ensure that Reviticell Kit commercialization is a success. Kaleidoscope (kascope.com) is a world‐class product‐design firm that has supported the successful launch of products for Fortune 50 companies.

Reviticell Kits will make regenerative medicine treatments available on a massive scale with applications ranging from wound-care in battlefield hospitals to anti-aging in Beverly Hills clinics. The emerging field of regenerative medicine is projected to grow to an $83 billion industry by 2020.

The International Search Authority provided Reviticell with a Written Opinion which states that 55 Reviticell patent claims are novel, inventive, and have industrial applicability. This favorable Written Opinion means that Reviticell is now eligible to take advantage of the Patent Prosecution Highway which is a simple procedure that allows these patent claims to go through an accelerated examination by the US Patent Office. The Patent Prosecution Highway will also allow Reviticell to obtain stable patent rights efficiently around the world.

Doctors can be as confident with treatments prepared with Reviticell Kits as they would be with treatments manufactured in highly-regulated labs. Doctors can also be confident that their patients won’t reject these treatments since their patient’s body is the source of what is being prepared.

Reviticell Holdings Inc., is a privately held company based in Jacksonville, Florida. Private Equity Investors are invited to contact Reviticell for possible investment opportunities.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mark Vickers
Visit website